Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Status:
Completed
Trial end date:
2008-11-19
Target enrollment:
Participant gender:
Summary
The study will test aprepitant for the prevention of CINV in patients receiving their initial
cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of
chemotherapy may opt to participate in an optional second cycle during which the patient will
receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant
will be given in place of the oral formulation on study day one. Study drug administration on
subsequent days will be given orally as in cycle 1.